BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer

Reuters03-02

March 2 (Reuters) - AIM ImmunoTech Inc AIM.A:

AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCER
AIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGEN

Source text: ID:nGNXzn7Pq

Further company coverage: AIM.A

((Reuters.Briefs@thomsonreuters.com;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2616435850?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-02 22:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2616435850","market":"fut","top_or_hot":-1,"title":"BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer</title></head><body><p><span>March 2 (Reuters)</span><span> - </span>AIM ImmunoTech Inc <span>AIM.A</span>:</p><ul><li><p>AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCER</p></li><li><p>AIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGEN</p></li></ul><p>Source text: <span>ID:nGNXzn7Pq</span></p><p>Further company coverage: <span>AIM.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-02 22:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic Cancer</title></head><body><p><span>March 2 (Reuters)</span><span> - </span>AIM ImmunoTech Inc <span>AIM.A</span>:</p><ul><li><p>AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCER</p></li><li><p>AIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGEN</p></li></ul><p>Source text: <span>ID:nGNXzn7Pq</span></p><p>Further company coverage: <span>AIM.A</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR资本管理(全球第二大对冲基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nTUA6TMRD9:1","article_id":"2616435850","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2616435850","pubTimestamp":1772460111,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic CancerMarch 2 (Reuters) - AIM ImmunoTech Inc AIM.A:AIM IMMU","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU2764262908.HKD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (HKD) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU1854104046.USD":"M&G (LUX) POSITIVE IMPACT \"A\" (USD) ACC","BK4535":"淡马锡持仓","BK4557":"大麻股","LU1923622614.USD":"Natixis Thematics Meta R/A USD","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU0096362180.USD":"CT (LUX) I GLOBAL FOCUS \"DU\" (USD)","LU0342679015.USD":"ALLIANZ GLOBAL EQUITY UNCONSTRAINED \"AT\" (USD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU2125909593.SGD":"Natixis Thematics Meta R/A SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","LU0957791311.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"ZU\" (USD) ACC","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2720916845.USD":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (USD) ACC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU2125910179.SGD":"Natixis Thematics Water H-R/A SGD","LU2433249047.HKD":"THEMATICS META \"R/A\" (HKD) ACC","TMO":"赛默飞世尔","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE0034235188.USD":"PINEBRIDGE GLOBAL FOCUS EQUITY \"A\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4121":"生命科学工具和服务","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2764263203.CNY":"BGF GLOBAL UNCONSTRAINED EQUITY \"A2\" (CNYHDG) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","AIM":"AIM ImmunoTech Inc.","BK4534":"瑞士信贷持仓","LU2360108059.USD":"BGF CIRCULAR ECONOMY \"A4\" (USD) INC","BK4585":"ETF&股票定投概念","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","LU1923621640.USD":"Natixis Thematics Water R/A USD"},"translate_title":"BRIEF-AIM Immunotech签署协议，规划Ampligen治疗晚期胰腺癌的拟议3期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIM":0.9,"TMO":0.9},"content_text":"BRIEF-AIM Immunotech Signs Agreement For Planning Of A Proposed Phase 3 Clinical Trial Of Ampligen In The Treatment Of Late-Stage Pancreatic CancerMarch 2 (Reuters) - AIM ImmunoTech Inc AIM.A:AIM IMMUNOTECH SIGNS AGREEMENT FOR PLANNING OF A PROPOSED PHASE 3 CLINICAL TRIAL OF AMPLIGEN IN THE TREATMENT OF LATE-STAGE PANCREATIC CANCERAIM IMMUNOTECH INC - SIGNS AGREEMENT WITH THERMO FISHER FOR PHASE 3 TRIAL OF AMPLIGENSource text: ID:nGNXzn7PqFurther company coverage: AIM.A ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2616435850","isCrawlerRequest":true}